Literature DB >> 7775459

Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells.

M Bouaboula1, B Bourrié, M Rinaldi-Carmona, D Shire, G Le Fur, P Casellas.   

Abstract

The recent isolation and cloning of the G protein-coupled central cannabinoid receptor (CB1) from brain tissue has provided a molecular basis to elucidate how cannabinoid compounds may mediate their psychoactive effects. Here we report the high expression of cannabinoid receptors in human astrocytoma tumors of different grades, in the astrocytoma cell lines U373 MG and GL-15, as well as in normal astrocytes. From an analysis of the coupling mechanisms of functional CB1 receptors in U373 MG, we show that, in addition to the inhibition of adenylyl cyclase, activation by the cannabinoid agonist CP-55940 induces the expression of the immediate-early gene krox-24, also known as NGFI-A, zif/268, egr-1, and TIS8. The amount of Krox-24 protein and the level of Krox-24 DNA binding activity, as measured by Western blot and electrophoretic mobility shift assay, respectively, were also increased by the addition of CP-55940. These effects were blocked by incubation with pertussis toxin but not by treatment with hydrolysis-resistant cAMP analogues, suggesting that the transduction pathway between the cannabinoid receptor and krox-24 involves a pertussis toxin-sensitive GTP-binding protein and is independent of cAMP metabolism. The specific involvement of CB1 in Krox-24 induction was demonstrated in Chinese hamster ovary cells transfected with the human CB1 receptor and also in experiments using the CB1-selective cannabinoid antagonist SR 141716A.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7775459     DOI: 10.1074/jbc.270.23.13973

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

Authors:  J J Rodriguez; K Mackie; V M Pickel
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

2.  Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Authors:  Belén G Ramírez; Cristina Blázquez; Teresa Gómez del Pulgar; Manuel Guzmán; María L de Ceballos
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

Review 3.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

4.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

5.  The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Brian F Thomas; Thuy Nguyen; Yanan Zhang; Jenny L Wiley
Journal:  Neuropharmacology       Date:  2017-08-10       Impact factor: 5.250

6.  delta 9-Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons.

Authors:  M L Hernández; L García-Gil; F Berrendero; J A Ramos; J J Fernández-Ruiz
Journal:  J Mol Neurosci       Date:  1997-04       Impact factor: 3.444

Review 7.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

8.  The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.

Authors:  T Gómez del Pulgar ; G Velasco; M Guzmán
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

Review 9.  Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue.

Authors:  Eiron Cudaback; Nephi Stella
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

10.  Altered white matter microstructure in adolescent substance users.

Authors:  Sunita Bava; Lawrence R Frank; Tim McQueeny; Brian C Schweinsburg; Alecia D Schweinsburg; Susan F Tapert
Journal:  Psychiatry Res       Date:  2009-08-20       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.